SALVO, Francesco; MICALLEF, Joelle; LAHOUEGUE, Amir; CHOUCHANA, Laurent; LETINIER, Louis; FAILLIE, Jean-Luc; PARIENTE, Antoine

doi:10.1080/14740338.2023.2227091

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

SALVO, Francesco

Bordeaux population health [BPH]

MICALLEF, Joelle

LAHOUEGUE, Amir

Idioma

Article de revue

Este ítem está publicado en

Expert Opinion on Drug Safety. 2023-07-01, vol. 22, n° 7, p. 541-548

Resumen en inglés

Artificial intelligence (AI) based tools offer new opportunities for pharmacovigilance (PV) activities. Nevertheless, their contribution to PV needs to be tailored to preserve and strengthen medical and pharmacological expertise in drug safety. This work aims to describe PV tasks in which the contribution of AI and intelligent automation (IA) tools is required, in the context of a continuous increase of spontaneous reporting cases and regulatory tasks. A narrative review with expert selection of pertinent references was performed through Medline. Two areas were covered, management of spontaneous reporting cases and signal detection. The use of AI and IA tools will assist a large spectrum of PV activities, both in public and private PV systems, in particular for tasks of low added value (e.g. initial quality check, veriﬁcation of essential regulatory information, search for duplicates). Testing, validating, and integrating these tools in the PV routine are the actual challenges for modern PV systems, to guarantee high-quality standards in terms of case management and signal detection.< Leer menos

Palabras clave en inglés

Artificial intelligence

Digital twins

Explainability

Human intelligence

Machine learning

Regulation

System interoperability

Metadatos

Compartir este ítem

Licencia de uso del documento

Will the future of pharmacovigilance be more automated?

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación